In decision-making on optimal treatment strategies, it is of great importance to identify variables that are involved in the decision rule, i.e. those interacting with the treatment. Effective variable selection helps to improve the prediction accuracy and enhance the interpretability of the decision rule. We propose a new penalized regression framework which can simultaneously estimate the optimal treatment strategy and identify important variables. The advantages of the new approach include: (i) it does not require the estimation of the baseline mean function of the response, which greatly improves the robustness of the estimator; (ii) the convenient loss-based framework makes it easier to adopt shrinkage methods for variable selection, which greatly facilitates implementation and statistical inferences for the estimator. The new procedure can be easily implemented by existing state-of-art software packages like LARS. Theoretical properties of the new estimator are studied. Its empirical performance is evaluated using simulation studies and further illustrated with an application to an AIDS clinical trial.
Introduction
An optimal treatment strategy is a set of treatment decision rules tailored for individuals, to maximize long-term clinical outcomes and reduce the risk of over-or under-treatment for individual patients. Personalized medicine takes into account individual heterogeneity in clinical, genetic, social, environmental, behaviour characteristics and so on, and has gained much attention in many disease studies like cancer. As in the lymphoma study, 1 the patient subtypes identified by tumour gene expression profiles showed different responses to CHOP and RCHOP treatments and thus individuals' tumour subtype should be considered for treatment assignment in addition to other clinical information.
Let Y denote the real-valued response, A 2 A denote the treatment received by the patient, where A is the set of available treatment methods, and X 2 X & R p denote the baseline covariates such as clinical measurements and medical history, which can be used for treatment assignment. We focus on a simple two-treatment regime, A ¼ {0, 1}: 0 is for the control/standard treatment and 1 for the new treatment. A treatment regime is a mapping g : X ! {0, 1}. The optimal treatment regime is a decision rule g opt that assigns the best treatment to a patient based on the observed covariates X. In practice, we collect data (Y i , A i , X i ), i ¼ 1, . . . ,n from a randomized clinical trial and the goal is to estimate g opt from data. Estimation of an optimal treatment strategy can be challenging, as the underlying relationship between the response and relevant prognostic factors may be quite complicated. For randomized studies, the potential outcome model 2 provides an effective tool for analyzing the causal effect of time-independent treatment. Rubin 3, 4 extend the potential outcome model for observational studies. Since then, there are a large number of works on optimal dynamic treatment regimes using Q-or A-learning algorithms, including the references. [5] [6] [7] [8] [9] [10] [11] With rapid advances in technology and combinations of diverse data sources, a very large number of prognostic factors such as clinical measurements, tumour pathology, and genetic information are available for estimating the optimal treatment strategy. However, many of them might not be related to the disease or the treatment assignment. As such, there is a lot of redundant information, and variable selection becomes necessary and plays an important role for making an optimal decision rule that is interpretable and efficient. In this article, we focus on variable selection for optimal treatment strategies. In the context of linear regression models, various methods have been developed for selecting variables that are important for prediction. These methods often lead to a better predictive model in practice. Recent developments in variable selection include shrinkage regression methods such as least absolute shrinkage and selection operator (LASSO) penalty, 12 smoothly clipped absolute deviation (SCAD) penalty, 13, 14 and adaptive LASSO penalty [15] [16] [17] ). The SCAD and adaptive LASSO are shown to be oracle when the tuning parameter is properly chosen.
However, there is scarce research on variable selection for optimal decision-making on treatment strategies. Compared to standard regression problems, the main goal here is to identify important variables involved in treatment decision rules. Recently, in the framework of Q-learning, Qian and Murphy 18 developed a two-step procedure which estimates the conditional means first and then derived the treatment rule based on estimated conditional means, and l 1 penalty was employed for variable selection. The paper 19 proposed a new ranking method to variable selection in this context, in which they discussed the concepts of predictive variables and prescriptive variables: the former refers to variables which reduce the variability and increase the accuracy of the estimator, and the latter refers to variables which help prescribe the optimal action. In this article, we propose a new lossbased framework to estimate the optimal treatment strategy. The new method is equipped with a convenient quadratic loss, which greatly facilitates the variable selection process by incorporating shrinkage penalties in the estimation. Moreover, the new loss function corresponds to a form of A-learning; therefore, the estimation does not require a correct specification of the baseline mean function and is robust. The remainder of the article is organized as follows. In Section 2, we introduce the new loss function and propose the penalized regression framework. We also study large-sample properties of the estimator and present a computational algorithm. We demonstrate simulation results inSection 3 and apply the method to data from an AIDS study in Section 4. Section 5 contains some discussions. All the proofs are relegated to the Appendix section.
Method 2.1 New estimation framework
We first give a brief review on the potential outcome. Based on reference, 3 the potential outcome Y * (a) is the outcome value that would result if a patient was assigned to the treatment a 2 A. For a patient with covariates X ¼ x, the goal is to find the optimal treatment regime that maximizes the expected outcome, i.e. g opt (X) ¼ arg max g2G E[Y * (g(X))], where G denote the set of all possible treatment regimes. Following, 3 two assumptions are typically required for computing the expectation of the potential outcome:
(C1) The outcome of one patient is not influenced by the treatment allocation of other subjects. Or equivalently,
. This is also known as consistency assumption; (C2) The treatment assignment for an individual is independent of the potential outcomes conditional on X. In other words, A ? {Y * (a)} a 2 A W X. This essentially assumes no unmeasured confounders. Under these two assumptions, it is easy to show that
Therefore, g opt can be expressed as
Consider the following general model E(YW X, A) ¼ h 0 (X) + Af(X). Here, h 0 (X) presents the baseline effects of X on Y and f(X) describes the combination of marginal treatment effect and its interaction effects with covariates. It is easy to show that E(YW X ¼
. Therefore, for a patient with covariates X ¼ x, the optimal treatment is g opt (
For consistent estimation of the optimal treatment rule, it is usually assumed (C3) 0 < (x) < 1, 8x 2 X and E[(X)(1 À (X))XX T ] is finite and non-degenerate.
In randomized studies, (x) is actually known and it is the treatment assignment probability predetermined by design. Throughout the article, we assume that conditions (C1)-(C3) hold.
To simplify the optimal treatment strategy, we consider the linear form for the interaction effect, also known as the contrast, i.e.
EðYjX, AÞ
The primary interest is to estimate the contrast or interaction function b T e X, but not the baseline h 0 (X). Given the observations {Y i , X i , A i ; i ¼ 1, . . . ,n}, we propose to minimize the following loss function
where (x) is an arbitrary function. It is interesting to note that, when taking the derivative of L n, (b) with respect to b, the resulting estimating equation has a form of A-learning. 7 Therefore L n, (b) provides a loss function in the framework of A-learning. In practice, we suggest to use a parametric form for (Á) and minimizes
Two feasible choices of are: the constant model (x; c) ¼ and the linear model ðx;
Denote the solution to (2.2) as ðe c T , e b T Þ T . Asymptotic properties of e b are studied in the following session. Essentially, if (x) is known as in randomized studies, we can show that e b is a consistent estimator for b 0 , regardless of the choice of (x; c). This robustness is a desired property for both model estimation and variable selection. The optimal decision rule only depends on the treatment and treatment-covariates interaction effects b T e X, and so the important variables are those with non-zero coefficients. The convenient loss form in (2.2) makes it easy to adopt shrinkage penalties for variable selection. In order to select important prescriptive variables, we propose to solve min b L n ðb,e cÞ þ n X pþ1 j¼1 Jðj j jÞ, ð2:3Þ
where n is a tuning parameter and J a shrinkage penalty. There are plenty of choices for J, such as SCAD, adaptive LASSO and minimax concave penalty. 20 In this article, we employ the adaptive LASSO penalty for variable selection and solves min b L n ðb,e cÞ þ n X pþ1 j¼1 w j j j j: ð2:4Þ
As pointed out by Zou, 15 the values of weights w j 's are crucial to effective selection in practice. In general, large penalties are desired for unimportant covariates and small penalties for important ones. In this work, we use w À1
In the next session, we study the asymptotic properties of e b and b b.
Asymptotic properties
We study asymptotic properties of e b and b b. Proofs of theorems are given in the Appendix. Let S ¼ {j : j0 6 ¼ 0, j ¼ 1, . . . ,p + 1} denote the true set of important variables for the optimal decision. Without loss of generality,
. . , p þ 1g be the set of selected important variables. We have Theorem 1: If regularity conditions (A1)-(A4) in the Appendix hold, the linear treatmentcovariates interaction term in model (2.1) is correctly specified and (x) is known, then we have ffiffi ffi n p ð e b À b 0 Þ ! Nð0, VÞ as n ! 1, where V is given in the Appendix.
Theorem 2: Assume that ffiffi ffi n p n ! 0 and n n ! 1. Then, under the conditions of Theorem 1, we have: (i) (selection consistency) Pð b S ¼ SÞ !1 as n ! 1; (ii) (asymptotic normality) ffiffi ffi n p ð b b S À b 0,S Þ ! Nð0, AEÞ as n ! 1.
Remark: In observational studies, the propensity score (x) is usually not known in advance. A parametric model (x; a), such as logistic regression can be used to estimate (x). As long as the parametric model is correctly specified, the parameter can be consistently estimated by the maximum likelihood estimator b a. By replacing (X i ) in (2.2) and (2.4) by ðX i ;b aÞ, similar results as given in Theorems 1 and 2 can also be established for the resulting estimators.
Computation and tuning
Let Y i ¼ Y i À ðX i ;e cÞ and X i ¼ e X i fA i À ðX i Þg. The loss function L n ðe c, bÞ ¼ ð1=nÞ P n i¼1 ðY i À b T X i Þ 2 has a standard quadratic form. The LARS algorithm 21 can be adapted to compute the entire solution path of (2.4). The following gives the algorithm:
.
Step 1: Minimize (2.2). Denote the minimizers as ð e b,e cÞ. .
Step 2: Construct the weights w À1 j ¼ j j j for j ¼ 1, . . . ,p + 1. . Step 3: Compute Y i and X i , i ¼ 1, . . . ,n. Solve the penalized least squared estimation in (2.4) using the LARS to obtain the whole solution path of b. For a fixed , denote the solution by b bðÞ.
We use a BIC-type criteria 15 to select the tuning parameter . Specifically, we minimize L n ð b bðÞ,e cÞ=L n ð e b,e cÞ þ d ðÞ logðnÞ=n: to obtain an estimator of , where d() is the number of nonzeros in b bðÞ.
Simulations
We evaluate the empirical performance of the new method in terms of estimation accuracy and variable selection under various settings. Assume the randomized trial with ¼ 0.5. We consider different function forms for the baseline h 0 , including a simple linear form, a complex non-linear form and a function containing interactions between the covariates. Also, we allow important variables in the baseline to be different from those in the contrast function. Define e X ¼ ð1, X T Þ T and 0 d for the zero vector of length d.
Low dimension examples
We consider the following three models with p ¼ 10,
. ,X 10 ) T are multivariate normal with mean 0, variance 1, and the correlation Corr(X j , X k ) ¼ 0.5 W j À kW . The error term $ N(0, 0.5 2 ). The coefficients To evaluate the model estimation performance of the estimator, we report its mean squared error
The average MSE over 500 realizations are reported and so are the corresponding standard errors (in parentheses). To evaluate variable selection performance, we summarize the number of correct zero coefficients identified (denoted as 'Corr0'), the number of non-zero effects incorrectly identified as zero (denoted as 'Incorr0') and the proportion of exactly selecting the correct model (denoted as 'Exact') among 500 replications. We also report the frequency of being selected for each variable. To evaluate the accuracy of a treatment assignment rule Iðb T e X 4 0Þ, we calculate the average percentage of making correct decisions (PCDs) over 500 simulation runs, i.e. mean of 1 À P n i¼1 jIðb T e X i 4 0Þ À Iðb T 0 e X i 4 0Þj=n. For comparison, we report the PCDs of both the unpenalized estimator e b (denoted as 'Unpen.') and the penalized estimator b b (denoted as 'Penalized').
We compare two cases which correspond to different working models for :
. Case 1: Set (X; c) , a constant model. . Case 2: Set ðX; cÞ c T e X, a linear model. Table 1 summarizes the estimation, selection and PCD results for Model I under two cases. We consider three different sample sizes: n ¼ 100, 200 and 400. For each case, both the MSE and classification error improve as the sample increases, which is expected. The proposed method gives an overall good performance in variable selection, especially when the sample size is large. For example, when n ¼ 400, the frequencies of selecting the exact true model are, respectively, 70.6% and 91.0% in Cases 1 and 2. The estimator in Case 2 consistently shows better performance than that in Case 1, in terms of both model estimation and variable selection. With regard to the PCD, the fit in Case 2 again yields higher accuracy than Case 1. Furthermore, the penalized estimator overall gives smaller PCD than the unpenalized estimator, except in Case 1 when the sample size is small. FromTable 2, we observe that the new procedure is very effective in retaining important variables: intercepts, X 1 , X 9 and X 10 in the model and removing noise variables from the model, especially when the sample size is moderately large. Tables 3-6 summarizes the estimation, selection and PCD results for Models II and III. Overall, the new procedure performs well for variable selection, and the penalized estimator produces smaller PCDs than the unpenalized estimator. In both models, the fit in Case 2 gives better performance than Case 1 with regard to model estimation, variable selection and PCD. These simulation results suggest that a posited model with a rich structure generally works better than a simple model.
Large dimension examples
We now increase the input dimension to p ¼ 50 and check the performance of the new procedure under larger dimensional settings. We consider Models IV and V, 
. ,X 50 ) T are multivariate normal with mean 0, variance 1, and the correlation Corr(X j , X k ) ¼ 0.5 W j À kW , c 1 ¼ (1, À1, 0 48 ) T , c 2 ¼ (1, 0 2 , À1, 0 45 , 1) T and b ¼ (1, 1, 0 46 , À0.9, 0.8) T . Other settings are the same as in Model I. Tables 7 and 8 summarize variable selection and estimation results, respectively, for each model. In these large dimensional settings, we observe the significant gain in PCD for the penalized estimator compared with the unpenalized estimator. Also, the new procedure 
Application to AIDS study (ACTG175)
We apply our method to data from AIDS Clinical Trials Group Protocol 175 (ACTG175), which contains 2139 HIV-infected subjects. In ACTG175, study subjects were randomized to four different treatment groups: zidovudine (ZDV) monotherapy, ZDV + didanosine (ddI), ZDV + zalcitabine and ddI monotherapy. 22 As in refences, 23, 24 we chose the CD4 count (cells/mm 3 ) at 20 AE 5 weeks post-baseline as the primary continuous response Y. Besides the treatment indicator, we included the same 12 baseline covariates as considered by Tsiatis et al. 23 and Zhang et al. 24 in our model, which consist of five continuous covariates: age (years), weight (kg), Karnofsky score (scale of 0-100), CD4 count (cells/mm 3 ) at baseline and CD8 count (cells/mm 3 ) at baseline, and seven binary covariates: hemophilia (0¼no, 1¼yes), homosexual activity (0¼no, 1¼yes), history of intravenous drug use (0¼no, 1¼yes), race (0¼white, 1¼non-white), gender (0¼female, 1¼male), antiretroviral history (0¼naive, 1¼experienced) and symptomatic status (0¼asymptomatic, 1¼symptomatic). The goal of our study is to find the optimal treatment to maximize the expected CD4 count (cells/mm 3 ) at 20 AE 5 weeks post-baseline. We fit model (2.1) with X being the 12 baseline covariates. For the treatment indicator A, we considered the following four analyses:
. In our analysis, we assumed the linear model for h(x; c). For analysis 1, the adaptive LASSO estimator b b ¼ ð48:46, 0, . . . , 0Þ T , implying that the other three treatments are uniformly better than zidovudine (ZDV) monotherapy and all the patients should be assigned to the other three treatments. For analysis 2, except for the intercept, the new estimator also selects two important covariates: age and homosexual activity (homo), and their corresponding estimates are À44.92, 2.52, and À21.31, respectively. Therefore, the optimal treatment rule is I(À44.92+2.52 * age À21.31 * homo > 0) for comparing treatments ZDV+didanosine (ddI) (A ¼ 1) and treatment ZDV+zalcitabine (A ¼ 0), or equivalently, for a patient with homo ¼ 0, assign to treatment 1 if age > 17.8 and treatment 0 otherwise; while for a patient with homo ¼ 1, assign to treatment 1 if age > 26.3 and treatment 0 otherwise. Note that the age of study subjects ranges from 12 to 70. According to the obtained optimal treatment rule, 978 out of 1046 patients (93.5%) in this subset should be assigned to treatment ZDV+didanosine (ddI). It is also noted that treatment ZDV+zalcitabine is more favorable to young patients with AIDS. For analysis 3, except for the intercept, the new estimator also selects three important covariates: age, CD4 count at baseline (CD40) and homo, and their corresponding estimates are 71.59, 1.07, À0.18, and À33.57, respectively. This leads to the optimal treatment rule I(71.59 + 1.07 * age À 0.18 * CD40 À 33.57 * homo > 0) when comparing treatments ZDV+didanosine (ddI) (A ¼ 1) and ddI monotherapy (A ¼ 0). According to the obtained optimal treatment rule, 878 out of 1083 patients (81.1%) in this subset should be assigned to treatment ZDV+didanosine (ddI). For analysis 4, the adaptive LASSO selects no covariates including intercept, i.e. b b ¼ 0, suggesting that treatments ZDV+zalcitabine and ddI monotherapy are equally good for all patients in this subset.
Discussion
In this article, we propose a new loss-based estimation framework for estimating the optimal treatment strategy, which naturally leads to a penalized framework for variable selection and sparse estimation. One desired property of the new approach is that it does not require the correct specification of the baseline function in order to produce consistent estimation and variable selection for the optimal treatment rule, as long as the interaction function form is correct. Numerical results suggest that the posited baseline model with a richer structure tends to improve the estimation efficiency.
This study focuses on a two-treatment setup. In practice, the number of treatment options can be more than two, and the optimal treatment amounts to selecting the treatment which produces the largest gain in the outcome. It would be interesting to extend this methodology to multipletreatment settings. Variable selection is more complicated for multiple treatments, since the decision rule involves multiple comparisons among candidate treatments. Moreover, for dynamic treatment regimes, a sequence of decision rules are needed, one per time interval, throughout an individual's disease course. We study the variable selection problem at one decision point in this study, and plan to extend the new framework to dynamic-treatment regimes.
